Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. de With · SciRah

Researcher profile · Semantic Scholar

M. de With

Share profile

M. de With — researcher profile on SciRah

h-index: 12
Works: 30
Citations: 422

Most-cited papers

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
M. de With, A. Sadlon, E. Cecchin, V. Haufroid +5 more
2023ESMO Open72 citations Open access
Semantic Scholar
CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?
Tessa A. Mulder, R. A. G. van Eerden, M. de With, L. Elens +5 more
2021Frontiers in Genetics69 citations Open access
Semantic Scholar
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
M. de With, J. Knikman, Femke M. de Man, Carin A. T. C. Lunenburg +18 more
2022Clinical pharmacology and therapy54 citations Open access
Semantic Scholar
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
E. Hulshof, M. de With, Femke M. de Man, G. Creemers +17 more
2022European Journal of Cancer42 citations Open access
Semantic Scholar
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
Tessa A. Mulder, M. de With, M. Del Re, R. Danesi +2 more
2021Cancers39 citations Open access
Semantic Scholar
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
M. de With, L. van Doorn, E. Kloet, Anne van Veggel +7 more
2023Clinical Pharmacokinetics23 citations Open access
Semantic Scholar
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
M. de With, L. van Doorn, D. Maasland, Tessa A. Mulder +7 more
2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie19 citations Open access
Semantic Scholar
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
Femke M. de Man, K. Hussaarts, M. de With, Esther Oomen-de Hoop +7 more
2019Clinical pharmacology and therapy19 citations Open access
Semantic Scholar
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
N. Heersche, G. D. Marijn Veerman, M. de With, S. Bins +5 more
2022Drug resistance updates16 citations Open access
Semantic Scholar
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
M. de With, D. Hurkmans, Esther Oomen-de Hoop, A. Lalouti +8 more
2021Cancers16 citations Open access
Semantic Scholar
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
J. Knikman, M. de With, N. Heersche, M. Lopez-Yurda +24 more
2025European Journal of Cancer14 citations Open access
Semantic Scholar
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
E. Hulshof, M. de With, G. Creemers, H. Guchelaar +3 more
2022European Journal of Cancer12 citations Open access
Semantic Scholar
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
B. Belderbos, M. de With, Rajbir Singh, B. Agema +6 more
2020Cancer Chemotherapy and Pharmacology7 citations Open access
Semantic Scholar
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.
N. Heersche, Sofía L. J. Peeters, Doortje Böhm, S. Bohringer +18 more
2026The Journal of the National Comprehensive Cancer Network5 citations
Semantic Scholar
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
A. Goey, M. de With, B. Agema, E. O. Hoop +5 more
2019Pharmacogenomics (London)5 citations
Semantic Scholar
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.
M. de With, Gemma Brufau, Laila A. van den Berg, Femke M. de Man +10 more
2022JCO Precision Oncology4 citations Open access
Semantic Scholar
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
Sofía L. J. Peeters, N. Heersche, Doortje Böhm, Stefan Böhringer +19 more
2026The Lancet Regional Health - Europe3 citations Open access
Semantic Scholar
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
E. Hulshof, M. de With, Femke M. de Man, G. Creemers +11 more
20212 citations
Semantic Scholar
596P Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study
N. Heersche, J. Knikman, M. de With, M. Lopez-Yurda +16 more
2024Annals of Oncology1 citations
Semantic Scholar
70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study
M. de With, J. Knikman, A. Baars, G. Creemers +16 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib.
De F. R. Man, K. Hussaarts, M. de With, E. O. Hoop +6 more
2018Annals of Oncology1 citations Open access
Semantic Scholar
NP-012 Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan: a multicentre real-world study
Sofía L. J. Peeters, N. Heersche, D. M. Bohm, S. Bohringer +16 more
2026National poster winner abstracts0 citations
Semantic Scholar
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study.
J. Baltussen, J. Knikman, N. D. de Glas, M. de With +21 more
2026Journal of Geriatric Oncology0 citations Open access
Semantic Scholar
1686eP Local skin reactions due to topical 5-fluorouracil treatment: Does DPYD-genotype matter?
N. Heersche, M. de With, E. O. Hoop, S. Meier +9 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
2238P Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: Results of a multicentre survival analysis
N. Heersche, S. Peeters, D. M. Bohm, S. Böhringer +16 more
2025Annals of Oncology0 citations
Semantic Scholar
Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters”
M. de With, J. Knikman, J. Schellens, H. Gelderblom +5 more
2022Clinical pharmacology and therapy0 citations Open access
Semantic Scholar
71P Capecitabine-induced adverse events: A pharmacogenetic study beyond DPYD
M. de With, L. V. van Doorn, D. Maasland, T. Mulder +4 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
1128P Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy
M. de With, D. Hurkmans, E. O. Hoop, A. Lalouti +7 more
20200 citations Open access
Semantic Scholar
Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
B. Agema, S. Koolen, M. de With, N. van Doorn +7 more
2020Genes0 citations Open access
Semantic Scholar
Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients
B. C. Agema, S. Koolen, M. de With, N. Heersche +7 more
2019Annals of Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. V. van Schaik×25
Invite
R. V. van Schaik — researcher profile on SciRah
R. Mathijssen×21
Invite
R. Mathijssen — researcher profile on SciRah
S. Bins×15
Invite
S. Bins — researcher profile on SciRah
N. Heersche×10
Invite
N. Heersche — researcher profile on SciRah

×9

Invite

H. Guchelaar — researcher profile on SciRah

Femke M. de Man×8

Invite

Femke M. de Man — researcher profile on SciRah

Invite

E. Hulshof — researcher profile on SciRah

Invite

M. Deenen — researcher profile on SciRah

Invite

E. O. Hoop — researcher profile on SciRah

Invite

J. Knikman — researcher profile on SciRah

Invite

J. Swen — researcher profile on SciRah

Esther Oomen-de Hoop×6

Invite

Esther Oomen-de Hoop — researcher profile on SciRah